IL144307A0 - Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents - Google Patents
Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agentsInfo
- Publication number
- IL144307A0 IL144307A0 IL14430700A IL14430700A IL144307A0 IL 144307 A0 IL144307 A0 IL 144307A0 IL 14430700 A IL14430700 A IL 14430700A IL 14430700 A IL14430700 A IL 14430700A IL 144307 A0 IL144307 A0 IL 144307A0
- Authority
- IL
- Israel
- Prior art keywords
- heteroaryl
- anticancer agents
- derivatives useful
- substituted quinolin
- quinolin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11970299P | 1999-02-11 | 1999-02-11 | |
PCT/IB2000/000121 WO2000047574A1 (en) | 1999-02-11 | 2000-02-04 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
Publications (1)
Publication Number | Publication Date |
---|---|
IL144307A0 true IL144307A0 (en) | 2002-05-23 |
Family
ID=22385869
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL14430700A IL144307A0 (en) | 1999-02-11 | 2000-02-04 | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
Country Status (39)
Country | Link |
---|---|
US (3) | US6258824B1 (ja) |
EP (1) | EP1150973B1 (ja) |
JP (3) | JP4090200B2 (ja) |
KR (1) | KR20010102073A (ja) |
CN (1) | CN1340051A (ja) |
AP (1) | AP2001002241A0 (ja) |
AR (1) | AR028985A1 (ja) |
AT (1) | ATE297916T1 (ja) |
AU (1) | AU2124800A (ja) |
BG (1) | BG105860A (ja) |
BR (1) | BR0008202A (ja) |
CA (1) | CA2362394C (ja) |
CO (1) | CO5140097A1 (ja) |
CZ (1) | CZ20012910A3 (ja) |
DE (1) | DE60020812T2 (ja) |
DZ (1) | DZ3009A1 (ja) |
EA (1) | EA200100766A1 (ja) |
EE (1) | EE200100425A (ja) |
ES (1) | ES2243228T3 (ja) |
GT (1) | GT200000014A (ja) |
HK (1) | HK1042096A1 (ja) |
HN (1) | HN2000000019A (ja) |
HR (1) | HRP20010574A2 (ja) |
HU (1) | HUP0105231A3 (ja) |
ID (1) | ID29584A (ja) |
IL (1) | IL144307A0 (ja) |
IS (1) | IS5997A (ja) |
MA (1) | MA26718A1 (ja) |
NO (1) | NO20013909L (ja) |
OA (1) | OA11833A (ja) |
PA (1) | PA8490601A1 (ja) |
PE (1) | PE20001464A1 (ja) |
PL (1) | PL349839A1 (ja) |
SK (1) | SK11002001A3 (ja) |
SV (1) | SV2001000020A (ja) |
TN (1) | TNSN00028A1 (ja) |
TR (2) | TR200201297T2 (ja) |
WO (1) | WO2000047574A1 (ja) |
ZA (1) | ZA200106520B (ja) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EE04582B1 (et) * | 1998-07-06 | 2006-02-15 | Janssen Pharmaceutica N.V. | Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis |
PL349839A1 (en) * | 1999-02-11 | 2002-09-23 | Pfizer Prod Inc | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
AU781986B2 (en) * | 1999-11-05 | 2005-06-23 | Cytovia, Inc. | Substituted 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
ES2212971T3 (es) * | 1999-11-30 | 2004-08-16 | Pfizer Products Inc. | Derivados de quinolina utiles para la inhibicion de la farnesil protein transferasa. |
HN2000000266A (es) * | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
EP1253921A4 (en) * | 2000-01-28 | 2004-10-13 | Merck & Co Inc | TREATMENT AND PROPHYLAXIS OF PROSTATE CANCER WITH COX-2 SELECTIVE INHIBITORS |
JO2361B1 (en) * | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
EP1170011A1 (en) * | 2000-07-06 | 2002-01-09 | Boehringer Ingelheim International GmbH | Novel use of inhibitors of the epidermal growth factor receptor |
JP4974437B2 (ja) | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する6−[(置換フェニル)メチル]−キノリンおよびキナゾリン誘導体 |
EP1322650B1 (en) * | 2000-09-25 | 2008-09-24 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 6-heterocyclylmethyl quinoline and quinazoline derivatives |
JP4974439B2 (ja) * | 2000-09-25 | 2012-07-11 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ファルネシルトランスフェラーゼを阻害する6−ヘテロシクリルメチルキノリノン誘導体 |
DE60118225T2 (de) | 2000-09-25 | 2007-05-03 | Janssen Pharmaceutica N.V. | Chinolin- und chinazolinderivate und deren verwendung als farnesyl transferase inhibitoren |
AU2001293847B2 (en) * | 2000-10-02 | 2007-05-24 | Janssen Pharmaceutica N.V. | Metabotropic glutamate receptor antagonists |
DE60139080D1 (de) | 2000-11-21 | 2009-08-06 | Janssen Pharmaceutica Nv | Farnesyltransferase hemmende benzoheterocyclische derivate |
EP1347966B1 (en) | 2000-12-27 | 2006-03-08 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting 4-substituted quinoline and quinazoline derivatives |
DE60119383T2 (de) * | 2000-12-27 | 2007-04-19 | Janssen Pharmaceutica N.V. | Farnesyltransferasehemmende 4-heterocyclylchinolin- und chinazolinderivate |
ATE450531T1 (de) * | 2001-05-16 | 2009-12-15 | Cytovia Inc | Substituierte 4h-chromene und analoga als aktivatoren von caspasen und induktoren von apoptose, und deren verwendung als antikrebsmittel |
WO2002092076A1 (en) * | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
US6858607B1 (en) | 2001-05-16 | 2005-02-22 | Cytovia, Inc. | 7,8-fused 4H-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20030139332A1 (en) * | 2001-07-09 | 2003-07-24 | The Regents Of The University Of California | Use of matrix metalloproteinase inhibitors to mitigate nerve damage |
DE60231646D1 (de) | 2001-12-19 | 2009-04-30 | Janssen Pharmaceutica Nv | Durch c-verbundene imidazole substituierte 1,8-annellierten chinolon-derivate als farnesyl transferase inhibitoren |
US7241777B2 (en) | 2002-03-22 | 2007-07-10 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
NZ535438A (en) * | 2002-03-29 | 2006-08-31 | Janssen Pharmaceutica Nv | Radiolabelled quinoline and quinolinone derivatives and their use as metabotropic glutamate receptor ligands |
AU2003229688B2 (en) | 2002-04-15 | 2009-07-30 | Janssen Pharmaceutica N.V. | Farnesyl transferase inhibiting tricyclic quinazoline derivatives substituted with carbon-linked imidazoles or triazoles |
WO2003097806A2 (en) | 2002-05-16 | 2003-11-27 | Cytovia, Inc. | Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US7476741B2 (en) | 2002-05-16 | 2009-01-13 | Cytovia, Inc. | Substituted 4H-chromens, 2H-chromenes, chromans and analogs as activators of caspases and inducers of apoptosis and the use thereof |
US20040186160A1 (en) * | 2002-12-13 | 2004-09-23 | Sugen, Inc. | Hexahydro-cyclohepta-pyrrole oxindole as potent kinase inhibitors |
EP1585743B1 (en) * | 2002-12-19 | 2007-05-23 | Pfizer Inc. | 2-(1h-indazol-6-ylamino)- benzamide compounds as protein kinases inhibitors useful for the treatment of ophthalmic diseases |
CA2517256C (en) | 2003-02-26 | 2013-04-30 | Sugen, Inc. | Aminoheteroaryl compounds as protein kinase inhibitors |
WO2004076446A1 (ja) * | 2003-02-27 | 2004-09-10 | Chugai Seiyaku Kabushiki Kaisha | ベンゾチオフェン誘導体 |
BRPI0412876A (pt) * | 2003-07-22 | 2006-10-03 | Janssen Pharmaceutica Nv | derivados de quinolinona como inibidores de c-fms quinase |
JP4691041B2 (ja) | 2003-11-20 | 2011-06-01 | チルドレンズ ホスピタル メディカル センター | Gtpアーゼ阻害剤および使用方法 |
WO2005089504A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089496A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
US20070293539A1 (en) * | 2004-03-18 | 2007-12-20 | Lansbury Peter T | Methods for the treatment of synucleinopathies |
WO2005089502A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
WO2005089515A2 (en) * | 2004-03-18 | 2005-09-29 | The Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
BRPI0509580A (pt) * | 2004-03-30 | 2007-11-27 | Pfizer Prod Inc | combinações de inibidores de transdução de sinal |
WO2006021881A2 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors |
EP1786785B9 (en) * | 2004-08-26 | 2013-05-22 | Pfizer Inc. | Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors |
EP1786777A1 (en) * | 2004-08-26 | 2007-05-23 | Pfizer, Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
AU2005294430A1 (en) * | 2004-10-07 | 2006-04-20 | Cytovia, Inc. | Substituted N-aryl-1H-pyrazolo[3,4-b]quinolin-4-amines and analogs as activators of caspases and inducers of apoptosis |
WO2007016539A2 (en) | 2005-07-29 | 2007-02-08 | Children's Hospital Medical Center | Gtpase inhibitors and methods of use and crystal structure of rac-1 gtpase |
CA2621371C (en) * | 2005-09-07 | 2018-05-15 | Amgen Fremont Inc. | Human monoclonal antibodies to activin receptor-like kinase-1 |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
EP1968591A4 (en) * | 2005-12-23 | 2010-02-17 | Link Medicine Corp | TREATMENT OF SYNUCLEINOPATHIES |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
EA200802058A1 (ru) | 2006-05-09 | 2009-06-30 | Пфайзер Продактс Инк. | Производные циклоалкиламинокислот и их фармацевтические композиции |
DK2056874T3 (da) | 2006-08-21 | 2012-10-15 | Hoffmann La Roche | Tumorterapi med et anti-vegf-antistof |
SI2155733T1 (sl) * | 2007-05-23 | 2012-12-31 | Allergan, Inc | Ciklični laktami za zdravljenje glavkoma ali zvišanega očesnega tlaka |
AU2008256926B2 (en) * | 2007-05-23 | 2013-09-19 | Allergan, Inc. | ((Bicylicheteroaryl) imidazolyl) methylheteroaryl compounds as adrenergic receptor agonists |
US8129356B2 (en) * | 2007-10-01 | 2012-03-06 | Vanderbilt University | Bmx mediated signal transduction in irradiated vascular endothelium |
US8232402B2 (en) * | 2008-03-12 | 2012-07-31 | Link Medicine Corporation | Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications |
DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US20110060005A1 (en) * | 2008-11-13 | 2011-03-10 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
US20100331363A1 (en) * | 2008-11-13 | 2010-12-30 | Link Medicine Corporation | Treatment of mitochondrial disorders using a farnesyl transferase inhibitor |
EP2370436A1 (en) * | 2008-11-13 | 2011-10-05 | Link Medicine Corporation | Azaquinolinone derivatives and uses thereof |
TW201041892A (en) | 2009-02-09 | 2010-12-01 | Supergen Inc | Pyrrolopyrimidinyl Axl kinase inhibitors |
US20120189641A1 (en) | 2009-02-25 | 2012-07-26 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
WO2010098866A1 (en) | 2009-02-27 | 2010-09-02 | Supergen, Inc. | Cyclopentathiophene/cyclohexathiophene dna methyltransferase inhibitors |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
EP2542893A2 (en) | 2010-03-03 | 2013-01-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
CA2783656A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013013188A1 (en) | 2011-07-21 | 2013-01-24 | Tolero Pharmaceuticals, Inc. | Heterocyclic protein kinase inhibitors |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
WO2013166043A1 (en) | 2012-05-02 | 2013-11-07 | Children's Hospital Medical Center | Rejuvenation of precursor cells |
WO2014062658A1 (en) | 2012-10-16 | 2014-04-24 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of ror-gamma-t |
EP2909193B1 (en) | 2012-10-16 | 2017-04-19 | Janssen Pharmaceutica NV | Phenyl linked quinolinyl modulators of ror-gamma-t |
EP2909189B8 (en) | 2012-10-16 | 2017-04-19 | Janssen Pharmaceutica NV | Heteroaryl linked quinolinyl modulators of ror-gamma-t |
US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
WO2014151871A2 (en) | 2013-03-14 | 2014-09-25 | Tolero Pharmaceuticals, Inc. | Jak2 and alk2 inhibitors and methods for their use |
US9206188B2 (en) | 2013-04-18 | 2015-12-08 | Arrien Pharmaceuticals Llc | Substituted pyrrolo[2,3-b]pyridines as ITK and JAK inhibitors |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
AU2014334616A1 (en) | 2013-10-15 | 2016-04-28 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORyt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
US9346782B2 (en) | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US10028503B2 (en) | 2014-06-18 | 2018-07-24 | Children's Hospital Medical Center | Platelet storage methods and compositions for same |
MX2018006781A (es) | 2015-12-03 | 2018-11-09 | Agios Pharmaceuticals Inc | Inhibidores de mat2a para el tratamiento del cancer que no expresen mtap. |
CN108003150A (zh) * | 2016-10-31 | 2018-05-08 | 河南工业大学 | 4-杂芳基喹啉酮衍生物的制备方法及其应用 |
KR20210038906A (ko) | 2018-07-26 | 2021-04-08 | 스미토모 다이니폰 파마 온콜로지, 인크. | 비정상적 acvr1 발현과 연관된 질환을 치료하는 방법 및 그에 사용하기 위한 acvr1 억제제 |
MX2021009371A (es) | 2019-02-12 | 2021-09-10 | Sumitomo Pharma Oncology Inc | Formulaciones que comprenden inhibidores de proteina cinasa heterociclicos. |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2732531A1 (de) * | 1977-07-19 | 1979-02-01 | Hoechst Ag | Imidazolcarbonsaeuren und deren derivate |
US4835154A (en) * | 1987-06-01 | 1989-05-30 | Smithkline Beckman Corporation | 1-aralykyl-5-piperazinylmethyl-2-mercaptoimidazoles and 2-alkylthioimidazoles and their use as dopamine-βhydroxylase inhibitors |
US5136085A (en) * | 1990-11-28 | 1992-08-04 | Glaxo Inc. | Synthesis of 2-aminobenzophenones |
US5053543A (en) * | 1990-11-28 | 1991-10-01 | Glaxo Inc. | Synthesis of 2-aminobenzophenones |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
ATE321757T1 (de) * | 1995-12-08 | 2006-04-15 | Janssen Pharmaceutica Nv | (imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren |
CN1231215C (zh) * | 1997-06-02 | 2005-12-14 | 詹森药业有限公司 | (咪唑-5-基)甲基-2-喹啉酮衍生物用作平滑肌细胞增殖抑制剂 |
PL346426A1 (en) | 1998-08-27 | 2002-02-11 | Pfizer Prod Inc | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents |
PL349839A1 (en) * | 1999-02-11 | 2002-09-23 | Pfizer Prod Inc | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents |
-
2000
- 2000-02-04 PL PL00349839A patent/PL349839A1/xx not_active Application Discontinuation
- 2000-02-04 CA CA002362394A patent/CA2362394C/en not_active Expired - Fee Related
- 2000-02-04 AP APAP/P/2001/002241A patent/AP2001002241A0/en unknown
- 2000-02-04 DE DE60020812T patent/DE60020812T2/de not_active Expired - Lifetime
- 2000-02-04 WO PCT/IB2000/000121 patent/WO2000047574A1/en active IP Right Grant
- 2000-02-04 TR TR2002/01297T patent/TR200201297T2/xx unknown
- 2000-02-04 TR TR2002/01296T patent/TR200201296T2/xx unknown
- 2000-02-04 AU AU21248/00A patent/AU2124800A/en not_active Abandoned
- 2000-02-04 ES ES00901292T patent/ES2243228T3/es not_active Expired - Lifetime
- 2000-02-04 EP EP00901292A patent/EP1150973B1/en not_active Expired - Lifetime
- 2000-02-04 JP JP2000598494A patent/JP4090200B2/ja not_active Expired - Fee Related
- 2000-02-04 KR KR1020017010187A patent/KR20010102073A/ko not_active Application Discontinuation
- 2000-02-04 SK SK1100-2001A patent/SK11002001A3/sk unknown
- 2000-02-04 CZ CZ20012910A patent/CZ20012910A3/cs unknown
- 2000-02-04 EE EEP200100425A patent/EE200100425A/xx unknown
- 2000-02-04 IL IL14430700A patent/IL144307A0/xx unknown
- 2000-02-04 CN CN00803668A patent/CN1340051A/zh active Pending
- 2000-02-04 AT AT00901292T patent/ATE297916T1/de not_active IP Right Cessation
- 2000-02-04 BR BR0008202-3A patent/BR0008202A/pt not_active IP Right Cessation
- 2000-02-04 EA EA200100766A patent/EA200100766A1/ru unknown
- 2000-02-04 ID IDW00200101724A patent/ID29584A/id unknown
- 2000-02-04 OA OA1200100212A patent/OA11833A/en unknown
- 2000-02-04 HU HU0105231A patent/HUP0105231A3/hu unknown
- 2000-02-09 DZ DZ000021A patent/DZ3009A1/xx active
- 2000-02-09 MA MA25905A patent/MA26718A1/fr unknown
- 2000-02-09 CO CO00008430A patent/CO5140097A1/es unknown
- 2000-02-09 HN HN2000000019A patent/HN2000000019A/es unknown
- 2000-02-09 US US09/501,163 patent/US6258824B1/en not_active Expired - Fee Related
- 2000-02-09 TN TNTNSN00028A patent/TNSN00028A1/fr unknown
- 2000-02-10 PA PA20008490601A patent/PA8490601A1/es unknown
- 2000-02-10 AR ARP000100589A patent/AR028985A1/es not_active Application Discontinuation
- 2000-02-10 GT GT200000014A patent/GT200000014A/es unknown
- 2000-02-10 PE PE2000000103A patent/PE20001464A1/es not_active Application Discontinuation
- 2000-02-10 SV SV2000000020A patent/SV2001000020A/es not_active Application Discontinuation
-
2001
- 2001-04-17 US US09/836,026 patent/US6388092B2/en not_active Expired - Fee Related
- 2001-07-10 IS IS5997A patent/IS5997A/is unknown
- 2001-07-30 HR HR20010574A patent/HRP20010574A2/hr not_active Application Discontinuation
- 2001-08-08 ZA ZA200106520A patent/ZA200106520B/en unknown
- 2001-08-10 NO NO20013909A patent/NO20013909L/no not_active Application Discontinuation
- 2001-08-30 BG BG105860A patent/BG105860A/xx unknown
-
2002
- 2002-03-07 US US10/092,744 patent/US6710209B2/en not_active Expired - Fee Related
- 2002-05-31 HK HK02104118.7A patent/HK1042096A1/zh unknown
-
2004
- 2004-02-05 JP JP2004029709A patent/JP4216740B2/ja not_active Expired - Fee Related
- 2004-07-20 JP JP2004211298A patent/JP2005002124A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PL349839A1 (en) | Heteroaryl-substituted quinolin-2-one derivatives useful as anticancer agents | |
AU4137400A (en) | Heterocyclic derivatives useful as anticancer agents | |
PL346426A1 (en) | Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents | |
AP2001002223A0 (en) | Substituted bicyclic derivatives useful as anticancer agents | |
PL351611A1 (en) | 4,5,6,7-tetrahydroindazole derivatives as antitumor agents | |
EG23817A (en) | 4-Phenyl-pyridine derivatives | |
GB9904103D0 (en) | Quinoline derivatives | |
IL138776A0 (en) | Isothiazole derivatives useful as anticancer agents | |
GC0000183A (en) | 3-Phenyl-pyridine derivatives | |
GC0000338A (en) | 5-Phenyl-pyrimidine derivatives | |
HK1044940A1 (zh) | 異噁唑咪唑羧酰胺衍生物 | |
GC0000191A (en) | 4-Phenyl-pyrimidine derivatives | |
GB9925880D0 (en) | B-Carboline derivatives | |
HK1045987A1 (zh) | 3-氨基-2-苄基-1-苯基-丙烷衍生物 | |
HK1048638A1 (zh) | Cyclopenteneone衍生物 | |
GC0000256A (en) | Ethanesulfonyl-piperidine derivatives | |
AU2199201A (en) | Anthracene derivatives as anti-cancer agents | |
AP2001002327A0 (en) | 1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives | |
AU5769500A (en) | Ucf116 derivatives as antitumor agents | |
GB9904104D0 (en) | Quinoline derivatives | |
GB9904105D0 (en) | Quinoline derivatives | |
GB9904102D0 (en) | Quinoline derivatives | |
GB9907134D0 (en) | Antimor napthylcombretastatin derivatives | |
HK1043987A1 (zh) | 硫-羥吲衍生物 |